@prefix this: <http://purl.org/np/RAsJA-5zi6dJjp4usxaEBKAWNaMX5Gm4A0SaEJ2tXX3Bc> .
@prefix sub: <http://purl.org/np/RAsJA-5zi6dJjp4usxaEBKAWNaMX5Gm4A0SaEJ2tXX3Bc#> .
@prefix np: <http://www.nanopub.org/nschema#> .
@prefix rdf: <http://www.w3.org/1999/02/22-rdf-syntax-ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .
@prefix rdfs: <http://www.w3.org/2000/01/rdf-schema#> .
@prefix biolink: <https://w3id.org/biolink/vocab/> .
@prefix ns1: <https://w3id.org/np/o/ntemplate/> .
@prefix prov: <http://www.w3.org/ns/prov#> .
@prefix npx: <http://purl.org/nanopub/x/> .

sub:Head {
  this: np:hasAssertion sub:assertion;
    np:hasProvenance sub:provenance;
    np:hasPublicationInfo sub:pubInfo;
    a np:Nanopublication .
}

sub:assertion {
  <http://purl.obolibrary.org/obo/MONDO_0005414> a biolink:Disease .
  
  sub:association rdf:object <http://purl.obolibrary.org/obo/MONDO_0005414>;
    rdf:predicate biolink:treats;
    rdf:subject <https://identifiers.org/DRUGBANK:DB00363>;
    a rdf:Statement;
    rdfs:label "There are no FDA or manufacturer guidelines for use of clozapine in pediatric population. Clozapine has been used in the treatment of refractory schizophrenia in child and adolescents. It is estimated that 40%–50% of patients with very early-onset schizophrenia (VEOS) are nonresponders to first-line neuroleptics and that clozapine is likely to be beneficial.";
    biolink:has_population_context sub:context;
    biolink:provided_by <https://w3id.org/um/NeuroDKG>;
    biolink:publications <https://pubmed.ncbi.nlm.nih.gov/31082865>;
    biolink:relation <https://w3id.org/um/neurodkg/OffLabelIndication> .
  
  sub:context a biolink:Cohort;
    rdfs:label "Children and adolescents" .
  
  <https://identifiers.org/DRUGBANK:DB00363> a biolink:Drug .
}

sub:provenance {
  sub:assertion prov:generatedAtTime "2021-08-24T16:18:41.079005"^^xsd:dateTime .
}

sub:pubInfo {
  sub:sig npx:hasAlgorithm "RSA";
    npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCamPJb4SzqpLXn//XJ5dlVfzz6QI+RPmiJTLXF/by2JR7sHMKRsCQDFsYMlq8zGHghOIkjRP9dpLZUtZzUcHt3MXiFKEPo8eGzUe9p+JXKFC8xxkJr94z2vq6IdMf71Iu1GH8SeDAKt/DgYO4zNaw8VuXvxnZRewKZSA+u8zWPVwIDAQAB";
    npx:hasSignature "GqUg4WbHoU9uPwnxqgk/swfXVKdvzxdJhvJ9YY8E908HaMctgR1zdOu0KOZm4NCRze1WVBnw61HdI3QQEHjtl8Flyr8OkoX/F9jwt0xxiJvs084eotPo6kUMSDMHF0+qqOQAzmTTRP0NyeZLXsPvwID3/xXTVolVW+IPtBnz7Bw=";
    npx:hasSignatureTarget this: .
  
  this: prov:generatedAtTime "2021-08-24T16:18:41.079005"^^xsd:dateTime;
    prov:wasAttributedTo <https://orcid.org/0000-0002-7641-6446>;
    ns1:wasCreatedFromTemplate <http://purl.org/np/RAhNHZw6Urw_Mccs4qy6Ws3C9CRuaHpQx8AwuApbWkqnY> .
}